PepGen Inc.

30/07/2024 | Press release | Distributed by Public on 30/07/2024 20:38

PepGen Announces Positive Data from Low Dose Cohort of PGN EDO51 in Ongoing CONNECT1 EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.